Treatment of [99mTc]Tc-hydroxy-diphosphonate ([99mTc]Tc-HDP) extravasation using hyaluronidase

Kevin R. Doornhof; Quido de Lussanet de la Sablonière; Stijn L.W. Koolen; Mark W. Konijnenberg

doi:10.1002/prp2.1232

Treatment of [99mTc]Tc-hydroxy-diphosphonate ([99mTc]Tc-HDP) extravasation using hyaluronidase

Kevin R. Doornhof^*, Quido de Lussanet de la Sablonière, Stijn L.W. Koolen, Mark W. Konijnenberg

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Extravasation of 99mTc-labeled radiopharmaceuticals is generally considered to require no specific intervention. In the presented case, the use of hyaluronidase could have minimized the adverse effects resulting from such an extravasation. Currently, no guidelines exist regarding the use of hyaluronidase after extravasation of [99mTc]Tc-HDP. Considering the low risk of administering hyaluronidase, it should be considered to limit the risk of injury after extravasation of [99mTc]Tc-HDP.

Original language	English
Article number	e1232
Journal	Pharmacology Research and Perspectives
Volume	12
Issue number	4
DOIs	https://doi.org/10.1002/prp2.1232
Publication status	Published - Aug 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

Access to Document

10.1002/prp2.1232Licence: CC BY

Pharmacology Res Perspec - 2024 - Doornhof - Treatment of 99mTc Tc‐hydroxy‐diphosphonate 99mTc Tc‐HDP extravasationFinal published version, 1.08 MBLicence: CC BY

Cite this

@article{006b7da287d94d9bbe059ca7153c45bb,

title = "Treatment of [99mTc]Tc-hydroxy-diphosphonate ([99mTc]Tc-HDP) extravasation using hyaluronidase",

abstract = "Extravasation of 99mTc-labeled radiopharmaceuticals is generally considered to require no specific intervention. In the presented case, the use of hyaluronidase could have minimized the adverse effects resulting from such an extravasation. Currently, no guidelines exist regarding the use of hyaluronidase after extravasation of [99mTc]Tc-HDP. Considering the low risk of administering hyaluronidase, it should be considered to limit the risk of injury after extravasation of [99mTc]Tc-HDP.",

author = "Doornhof, {Kevin R.} and Quido de Lussanet de la Sabloni{\`e}re and Koolen, {Stijn L.W.} and Konijnenberg, {Mark W.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.",

year = "2024",

month = aug,

doi = "10.1002/prp2.1232",

language = "English",

volume = "12",

journal = "Pharmacology Research and Perspectives",

issn = "2052-1707",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Treatment of [99mTc]Tc-hydroxy-diphosphonate ([99mTc]Tc-HDP) extravasation using hyaluronidase

AU - Doornhof, Kevin R.

AU - de Lussanet de la Sablonière, Quido

AU - Koolen, Stijn L.W.

AU - Konijnenberg, Mark W.

N1 - Publisher Copyright: © 2024 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

PY - 2024/8

Y1 - 2024/8

N2 - Extravasation of 99mTc-labeled radiopharmaceuticals is generally considered to require no specific intervention. In the presented case, the use of hyaluronidase could have minimized the adverse effects resulting from such an extravasation. Currently, no guidelines exist regarding the use of hyaluronidase after extravasation of [99mTc]Tc-HDP. Considering the low risk of administering hyaluronidase, it should be considered to limit the risk of injury after extravasation of [99mTc]Tc-HDP.

AB - Extravasation of 99mTc-labeled radiopharmaceuticals is generally considered to require no specific intervention. In the presented case, the use of hyaluronidase could have minimized the adverse effects resulting from such an extravasation. Currently, no guidelines exist regarding the use of hyaluronidase after extravasation of [99mTc]Tc-HDP. Considering the low risk of administering hyaluronidase, it should be considered to limit the risk of injury after extravasation of [99mTc]Tc-HDP.

UR - http://www.scopus.com/inward/record.url?scp=85199570182&partnerID=8YFLogxK

U2 - 10.1002/prp2.1232

DO - 10.1002/prp2.1232

M3 - Article

C2 - 39054750

AN - SCOPUS:85199570182

SN - 2052-1707

VL - 12

JO - Pharmacology Research and Perspectives

JF - Pharmacology Research and Perspectives

IS - 4

M1 - e1232

ER -

Treatment of [99mTc]Tc-hydroxy-diphosphonate ([99mTc]Tc-HDP) extravasation using hyaluronidase

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this